Based on the Pharmacy Core Curriculum in France (written in 1994)

Contact: Professor J. ATKINSON, Laboratoire de Pharmacologie, Faculte de Pharmacie UHP-Nancy I, 5, rue Albert Lebrun - B.P. 403, 54001 Nancy Cedex, France. Tel: 33 (0)383.17.88.11: Fax 33 (0)383.17.88.79; atkinson@pharma.u-nancy.fr :: http://www.uhp.u-nancy.fr/Pharma/CRG

Section I ž Mathematics, physics and chemistry
Section II ž Life sciences
Section III - Section V - Medicinal Sciences.

V-1 Handling of xenobiotics
V-1-1 Principles drug absorption, diffusion, metabolism and excretion
V-1-2 Factors modifying drug handling : physiological (age, pregnancy), pathological, other drugs
V-1-3 Principles of pharmacokinetics, compartmental and other models
V-1-4 Biodisponibility, bio-equivalence
V-1-5 Principles of drug dosage schedules
V-2 Mechanisms of action
V-2-1 General principles : Interactions with and binding to other molecules (proteins, nucleic acids, lipids): Agonists and antagonists : conformation and allosterism Receptor activation, signal transduction and ion channels; In vitro and in vivo study of drug action : pD2, pA2, receptor reserve; Drug combinations : antagonism, synergy; Factors influencing the variability in drug response; Preclinical and clinical evaluation of drug action Study methods; Design and legislation
V-2-2 Pharmacological mechanisms; Neurotransmission and neuromodulation Pathophysiological response to injury (autaco‹ds : histamine, bradykinin, serotonin, eicosano‹ds, platelet-activating factor) and cytokines; Nitric oxide; Ion transfer; Enzyme inhibitors, false transmitters; Gene therapy; Free radicals
V-3 Structure-activity relationships, pharmacology, therapeutics (human and animal) and pharmacovigilance of drugs of synthetic or non-synthetic origin
V-3-1 Autonomic nervous system; Parasympathetic, parasympatholytic; Sympathetic, sympatholytic; Ganglion blockers;
V-3-2 Central nervous system; Anti-epilectics; Centrally acting muscle relaxants; Antiparkinson drugs; Morphine and related analgesics; Hypnotics and sedatives; Anxiolytic drugs; Antidepressants; Psychostimulants; Drugs for the treatment of migraine;
V-3-3 Cardiovascular system : drugs for the treatment of Heart failure; Angina; Dysrythmias; Arterial hypertension; Peripheral vasospastic disorders; Shock; Volume disorders;
V-3-4 Haemostatis; Primary : platelet aggregation; Secondary : coagulation, thrombolysis, fibrinolysis, Contact haemostasis
V-3-5 Respiration; Analeptics; Cough suppressant drugs; Bronchodilatators; Drugs for the treatment of asthma
V-3-6 Inflammation and rheumatoid arthritis; Stero‹ds; NSAIDs; Analgesic-antipyretic;
V-3-7 Metabolism; Hypoglycemic agents; Drugs for the treatment of hyperlipoproteinemias Drugs for the treatment of gout (uricosuric drugs, allopurinol, colchicine) Drugs for the treatment of cholelithiasis; Drugs for disorders of phosphate and calcium metabolism; Anorectic drugs and appetite stimulants; Retinoids; Drugs for the treatment of anaemia.

Suggestion for the Public health and environment Section IV Pathology, symptomatology, clinical chemistry of, sex, alcohol, smoking, nutrition (renal and liver failure, obesity), concomitant drug treatment; Design and optimisation of dosage regimens; Pharmacokinetics (multiple compartments); Extent and rate of availability, nonlinear pharmacokinetics, drug reservoirs

Back